GlassScriptPhysician profile
Jim C Kim
NPI 1992762769
$18,918.43
in general payments reported to CMS, 2019-2025
40 companies · $2,309 in 2025
The $2,309 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,732 · 2020: $2,425 · 2021: $2,194 · 2022: $3,823 · 2023: $2,043 · 2024: $3,393 · 2025: $2,309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,732 · Education: $12.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,732.31 |
| Education | $12.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $5,626.11 | 2019-2025 | Krystexxa, Enbrel, Otezla |
| Abbvie INC. | $2,217.29 | 2019-2025 | |
| Janssen Biotech, INC. | $1,490.75 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Intuitive Surgical, INC. | $1,071.06 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $980.50 | 2019-2025 | Orencia |
| Glaxosmithkline, LLC. | $970.88 | 2019-2025 | Benlysta |
| Novartis Pharmaceuticals Corporation | $921.69 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $781.89 | 2021-2025 | Saphnelo |
| Ucb, INC. | $590.86 | 2020-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $584.86 | 2019-2025 | |
| Genentech USA, INC. | $537.74 | 2019-2025 | Actemra, Gazyva |
| Celgene Corporation | $348.79 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $333.48 | 2023-2025 | Ofev, Cyltezo |
| Aurinia Pharma U.S., INC. | $324.37 | 2022-2025 | Lupkynis |
| Fresenius Kabi USA, LLC | $303.49 | 2023-2025 | Idacio, Adalimumab-Aacf |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $222.91 | 2019-2023 | Krystexxa |
| US Oncology Corporate, INC. | $191.96 | 2024 | |
| Organon LLC | $184.98 | 2022-2025 | Renflexis, Hadlima |
| Lilly USA, LLC | $171.05 | 2020-2023 | Taltz |
| Janssen Scientific Affairs, LLC | $153.36 | 2020-2022 | |
| Alexion Pharmaceuticals, INC. | $130.37 | 2019-2025 | Strensiq |
| Radius Health, INC. | $124.95 | 2019 | |
| Ani Pharmaceuticals, INC. | $66.58 | 2022-2023 | Purified Cortrophin Gel |
| Genzyme Corporation | $65.36 | 2023 | |
| Stryker Corporation | $63.20 | 2020 | |
| Scilex Pharmaceuticals INC. | $60.56 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $45.69 | 2024 | Acthar |
| Allergan, INC. | $42.74 | 2019 | |
| Invivyd INC | $42.34 | 2025 | Pemgarda |
| Alvogen INC | $41.91 | 2024-2025 | Teriparatide |
| Octapharma USA, INC. | $29.90 | 2024 | Octagam Immune Globulin (Human) |
| Sandoz INC. | $27.29 | 2025 | Jubbonti |
| Bio Products Laboratory USA, INC. | $25.65 | 2021 | |
| Tersera Therapeutics LLC | $24.87 | 2025 | Quzyttir |
| Ultragenyx Pharmaceutical INC. | $21.69 | 2024 | Crysvita |
| Shorla Oncology INC. | $21.14 | 2024 | |
| Sobi, INC | $20.40 | 2022 | |
| Tonix Medicines, INC. | $19.75 | 2025 | Tonmya |
| Kiniksa Pharmaceuticals, LTD. | $18.39 | 2023 | Arcalyst |
| Kiniksa Pharmaceuticals International, Plc | $17.63 | 2024 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jim Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.